Central Venous Pressure Guided Hydration Prevention for Contrast-Induced Nephropathy

NACompletedINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Cardio-Renal Syndrome
Interventions
PROCEDURE

hydration

Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration in all patients. Investigator monitored the central venous pressure (CVP) by placing an 5-French catheter in the jugular vein in the intervention group, and administration fluid rate was adjusted according to the CVP as follows: 3 ml/kg/h for CVP lower than 6 mmHg, 1.5 ml/kg/h for pressure of 6-12 mmHg, and 1ml/kg/h for pressure higher than 12 mmHg. The control group was hydrated with 0.9% sodium chloride at 1 ml/kg/h, continued for the duration of 12 h post-procedure in both groups. Thus, both study groups received intravenous fluids for the same duration but at different rates. All study participants received intra-arterial Visipaque(320 mg I/ml; GE Healthcare) iso-osmolar contrast medium.

DRUG

Visipaque

All study participants received intra-arterial (320 mg I/ml; GE Healthcare)

DRUG

0.9% sodium chloride fluid administration

DEVICE

5-French catheter

Trial Locations (1)

100853

Chinese People's Liberation Army General Hospital, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER

NCT02405377 - Central Venous Pressure Guided Hydration Prevention for Contrast-Induced Nephropathy | Biotech Hunter | Biotech Hunter